Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

1,168 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Characterization of health-related quality of life in heart failure patients with preserved versus low ejection fraction in CHARM.
Lewis EF, Lamas GA, O'Meara E, Granger CB, Dunlap ME, McKelvie RS, Probstfield JL, Young JB, Michelson EL, Halling K, Carlsson J, Olofsson B, McMurray JJ, Yusuf S, Swedberg K, Pfeffer MA; CHARM Investigators. Lewis EF, et al. Eur J Heart Fail. 2007 Jan;9(1):83-91. doi: 10.1016/j.ejheart.2006.10.012. Epub 2006 Dec 21. Eur J Heart Fail. 2007. PMID: 17188020 Free article.
Effect of the direct renin inhibitor aliskiren on left ventricular remodelling following myocardial infarction with systolic dysfunction.
Solomon SD, Shin SH, Shah A, Skali H, Desai A, Kober L, Maggioni AP, Rouleau JL, Kelly RY, Hester A, McMurray JJ, Pfeffer MA; Aliskiren Study in Post-MI Patients to Reduce Remodeling (ASPIRE) Investigators. Solomon SD, et al. Eur Heart J. 2011 May;32(10):1227-34. doi: 10.1093/eurheartj/ehq522. Epub 2011 Feb 10. Eur Heart J. 2011. PMID: 21317148 Clinical Trial.
Left ventricular systolic and diastolic function, remodelling, and clinical outcomes among patients with diabetes following myocardial infarction and the influence of direct renin inhibition with aliskiren.
Shah AM, Shin SH, Takeuchi M, Skali H, Desai AS, Køber L, Maggioni AP, Rouleau JL, Kelly RY, Hester A, Keefe D, McMurray JJ, Pfeffer MA, Solomon SD. Shah AM, et al. Eur J Heart Fail. 2012 Feb;14(2):185-92. doi: 10.1093/eurjhf/hfr125. Epub 2011 Sep 29. Eur J Heart Fail. 2012. PMID: 21965526 Free article. Clinical Trial.
Predictors of fatal and nonfatal cardiovascular events in patients with type 2 diabetes mellitus, chronic kidney disease, and anemia: an analysis of the Trial to Reduce cardiovascular Events with Aranesp (darbepoetin-alfa) Therapy (TREAT).
McMurray JJ, Uno H, Jarolim P, Desai AS, de Zeeuw D, Eckardt KU, Ivanovich P, Levey AS, Lewis EF, McGill JB, Parfrey P, Parving HH, Toto RM, Solomon SD, Pfeffer MA. McMurray JJ, et al. Am Heart J. 2011 Oct;162(4):748-755.e3. doi: 10.1016/j.ahj.2011.07.016. Am Heart J. 2011. PMID: 21982669 Clinical Trial.
Renal dysfunction in patients with heart failure with preserved versus reduced ejection fraction: impact of the new Chronic Kidney Disease-Epidemiology Collaboration Group formula.
McAlister FA, Ezekowitz J, Tarantini L, Squire I, Komajda M, Bayes-Genis A, Gotsman I, Whalley G, Earle N, Poppe KK, Doughty RN; Meta-analysis Global Group in Chronic Heart Failure (MAGGIC) Investigators. McAlister FA, et al. Circ Heart Fail. 2012 May 1;5(3):309-14. doi: 10.1161/CIRCHEARTFAILURE.111.966242. Epub 2012 Mar 22. Circ Heart Fail. 2012. PMID: 22441773
1,168 results